EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A single center experience on PI3K / AKT / MTOR signaling defects: Towards pathogenicity assessment for four novel defects

Hacer Neslihan Bildik iD, Saliha Esenboga iD, Sevil Oskay Halaclı iD, Betül Karaatmaca iD, Elif Soyak Aytekin iD, Nadira Nabiyeva iD, Ayşegul Akarsu iD, Melike Ocak iD, Baran Erman iD, Cagman Tan iD, Tugba Arikoglu iD, Ismail Yaz iD und 3 weitere

Pediatric Allergy and Immunology · 2024

DOI: 10.1111/pai.14245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Hacer Neslihan Bildik und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Child Health, Immunology, Hacettepe University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Signal Transduction, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hacettepe University Scientific Coordination Unit, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phosphoinositide 3 kinases (PI3K) are lipid kinases expressed in lymphocytes/myeloid cells. PI3K/AKT/mTOR signaling defects present with recurrent infections, autoimmunity, lymphoproliferation, and agammaglobulinemia.

Objective

To characterize the PI3K/AKT/mTOR pathway defects and perform pathway analyses to assess novel variant pathogenicity.

Methods

We included 12 patients (heterozygous PIK3CD ( n = 9) and PIK3R1 ( n = 1) (activated PI3K delta syndrome (APDS) with gain‐of‐function mutations) and homozygous PIK3R1 variant ( n = 2)), performed clinical/laboratory/genetic evaluation, and flow cytometric PI3K/AKT/mTOR pathway analyses.

Results

Median age at onset of complaints was 17.5 months (3 months to 12 years) and at diagnosis was 15.7 years (2.5–37) in APDS. Median diagnostic delay was 12.9 years (1.6–27). Recurrent respiratory tract infections (90%), lymphoproliferation (70%), autoimmune/inflammatory findings (60%), and allergy (40%) were common in APDS. Recurrent viral infections were present in 4/10 and malignancy (non‐Hodgkin lymphoma and testicular yolk sac tumor) was present in 2/10 in APDS. Low CD4+ T cells(5/8) with increased CD4+ effector memory (8/8) and CD4+ TEMRA cells (6/8) were present in the given number of APDS patients. We diagnosed tubulointerstitial nephritis, Langerhans cell histiocytosis, and late‐onset congenital adrenal hyperplasia in APDS. Allergic findings, lymphoproliferation/malignancy, and high IgM were present in the APDS but not in PIK3R1 deficiency. Low IgM/IgG/CD19 + B cell counts were characteristic in patients with PIK3R1 homozygous loss‐of function mutations.

Conclusion

Differential diagnosis with combined immunodeficiency and diseases of immune dysregulation make molecular genetic analysis crucial for diagnosing mTOR pathway defects. It is easy to differentiate APDS and homozygous PIK3R1 defects with specific laboratory features. Additionally, mTOR pathway functional analysis is a definitive diagnostic and pathogenicity assessment tool for novel APDS mutations. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesSignal TransductionProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesHumansMaleChildAdolescentChild, PreschoolFemaleInfantAdultYoung AdultPrimary Immunodeficiency DiseasesClass I Phosphatidylinositol 3-KinasesMutation

Stichwörter der Autor:innen

APDSPIK3CDPIK3R1agammaglobulinemiaautoimmunityimmune dysregulationlymphoproliferationvariants of unknown significance

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMTOR protein, humanClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Institute of Child Health, Immunology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Ihsan Dogramaci Childrens' Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Division of Immunology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Pediatric Allergy and Immunology, Ankara Bilkent City Hospital, Ankara, Turkey.
  • Can Sucak Research Laboratory for Translational Immunology, Hacettepe University, Ankara, Turkey.
  • Department of Pediatrics, Division of Allergy and Immunology, Mersin University Faculty of Medicine, Mersin, Turkey.

ORCID-Profile: Hacer Neslihan Bildik, Saliha Esenboga, Sevil Oskay Halaclı, Betül Karaatmaca, Elif Soyak Aytekin, Nadira Nabiyeva, Ayşegul Akarsu, Melike Ocak, Baran Erman, Cagman Tan, Tugba Arikoglu, Ismail Yaz, Begum Cicek, Ilhan Tezcan, Deniz Cagdas

Förderung

  • Hacettepe University Scientific Coordination Unit
  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

Zitieren

APA

Bildik, H. N., Esenboga, S., Halaclı, S. O., Karaatmaca, B., Aytekin, E. S., Nabiyeva, N., Akarsu, A., Ocak, M., Erman, B., Tan, C., Arikoglu, T., Yaz, I., Cicek, B., Tezcan, I., & Cagdas, D. (2024). A single center experience on PI3K / AKT / MTOR signaling defects: Towards pathogenicity assessment for four novel defects. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14245

Vancouver

Bildik HN, Esenboga S, Halaclı SO, Karaatmaca B, Aytekin ES, Nabiyeva N, et al. A single center experience on PI3K / AKT / MTOR signaling defects: Towards pathogenicity assessment for four novel defects. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14245

BibTeX
@article{Bildik2024,
  author = {Bildik, Hacer Neslihan and Esenboga, Saliha and Halaclı, Sevil Oskay and Karaatmaca, Betül and Aytekin, Elif Soyak and Nabiyeva, Nadira and Akarsu, Ayşegul and Ocak, Melike and Erman, Baran and Tan, Cagman and Arikoglu, Tugba and Yaz, Ismail and Cicek, Begum and Tezcan, Ilhan and Cagdas, Deniz},
  title = {A single center experience on PI3K / AKT / MTOR signaling defects: Towards pathogenicity assessment for four novel defects},
  journal = {Pediatric Allergy and Immunology},
  year = {2024},
  doi = {10.1111/pai.14245}
}
Kostenlos starten →